Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines
Trial details
- Registry ID
- NCT05320393
- Phase
- Phase 2
The FDA approved PrabotulinumtoxinA-Xvfs (Jeuveau) on 1 Feb 2019.
Drug identity checked against registry records
Also recorded as Jeuveau
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar LinesNCT05320393 | EOLS | Phase 2 | Completed | 2023-05-22Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2019-02-01Day | PrabotulinumtoxinA-XvfsEvolus, Inc. · EOLS | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA761085", "applicant_as_listed_by_fda": "EVOLUS INC", "brand_names": ["JEUVEAU"], "active_ingredients": ["PRABOTULINUMTOXINA-XVFS"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20190201", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |